structural and functional unit involving the pituitary, hypothalamus, neurotransmitter systems, and brain. In the event that any of these compartments is anatomically and/or functionally damaged, inappropriate GH secretion will result.
The diagnostic tools applied to prove that impaired growth in an individual is caused by impaired GH secretion must be considered in the light of the evolution of our knowledge of this unit as well as the development of diagnostic techniques. Thus, historically, the diagnosis of GHD has conventionally been made on the basis of empirical findings revealing that the magnitude of GH secretion following a given stimulus known to provoke the release of GH into the circulation is inappropriate compared with the response of normally growing children.
Several methodological aspects, such as the measurement of GH, GHstimulatory tests, spontaneous GH secretion, determination of urinary GH, and IGFs, are discussed in detail in the chapters by Ranke, Girard, AlbertssonWikland and Rosberg, and Blum [see this volume] . In addition, the Growth Hormone Research Society (GRS) has published consensus guidelines for the diagnosis of GHD in adults (1997) and children (2002) [GRS, 1997 [GRS, , 2000 . The aim of this chapter is to summarize and discuss some of the fundamental issues and questions related to the diagnosis of GHD.
Methodological Aspects of Measuring GH Secretion
In our current understanding, a variety of auxologically and clinically similar growth disorders exist that are based on different failures of the GH-IGF target tissue axis. Through different diagnostic tests it is possible to distinguish the level of impairment. Basically, these disorders can be divided into those relating to a primary abnormality of the GH axis and those involving secondary abnormalities (table 1) .
The diagnostic approach defining an impairment of GH secretion is still very much influenced by historical developments in this field. GH was the first hormone to be measured with a high degree of accuracy. However, its measurement still lacks a certain degree of standardization [Ranke et al., 1999] . The assays for determining IGFs and their binding proteins are also widely available; there is, however, no uniform level of standardization [Ranke et al., 2001] . Traditionally, most clinicians still diagnose GHD by initially measuring GH [Wyatt et al., 1995] ; our own approach, however, is to measure IGF-I and IGFBP-3 first [Ranke et al., 2000] .
The characteristic patterns displayed by the various parameters currently employed to define the different pathogenetic entities of the GHD syndrome are shown in table 1.
Theoretically, measurements of spontaneously secreted GH should give the most accurate insight into the physiological situation of the patient. However, as outlined in Albertsson-Wikland and Rosberg [this volume], a multitude of methodological aspects must be taken into account, such as the testing procedures used, the evaluation of the results, normative values, the variability of repeated tests, and not least, the convenience and cost of the procedure. For these reasons, the evaluation of spontaneous GH secretion has primarily remained a research tool and is usually restricted to special investigations. ↑ ↑ ↑ ↓ /n ↑ Therapy with GH possible n ϭ Normal; ↑ ϭ increased; ↓ ϭ diminished; GH ϭ growth hormone; GHRH ϭ growth hormonereleasing hormone; AB ϭ antibody; IGF-I ϭ insulin-like growth factor I; IGFBP-3 ϭ insulin-like growth factor binding protein 3.
Depending on the methodological approach and the individual experience of the investigator, the initial diagnostic approach to proving GHD taken by most investigators is either to measure IGF-I and/or insulin-like growth factor binding protein 3 (IGFBP-3) or to perform GH-stimulatory tests. The diagnostic approach to evaluating disorders of the GH axis is summarized in Appendix B [this volume, Chart 3]. This approach varies depending on whether GH, or alternatively IGF-I (or IGFBP-3), is selected as the entrance criterion.
If the physician begins by measuring GH after stimulating the GH secretion, the most difficult problem is to define the cut-off value distinguishing a normal from an impaired response. The response to different stimuli, as determined by the maximum GH level, varies not only according to the method of GH measurement chosen, but also according to the sex, age, and pubertal stage of the patient and the stimulatory power of the procedure (see below). At present, there is very little information on test results in children with normal stature, and what we know has become available only rather recently [Zadik et al., 1990; Marin et al., 1994; Ghigo et al., 1996a] . Truly normative data based on all the important covariables are thus practically unavailable for the majority of the tests used. The data also show that, even in normal children, the GH maximum observed can be below 10, 7, or even 5 g/l. (The issue of international reference preparations is discussed below.) Thus, if a cut-off level for defining the border between a 'normal' and a 'subnormal' response is stipulated to be 10 g/l, it is obvious that performing only one test will have as a consequence that a sizeable proportion of the children tested will be below this cutoff, and they will be misclassified as GH-deficient (error of the second order). If, for example, in 25% of normal children the GH response to a stimulus were Ͻ10 g/l -a percentage that is perhaps even too low -5% of the remaining children would be misclassified as GH-deficient even after a second test. It is therefore not surprising that, in studies in which patients with a diagnosis of GHD made many years ago were retested after the termination of GH treatment, a high percentage were found to have normal test results. In a series of patients reinvestigated by Cacciari et al. [1992] , the diagnosis was not confirmed in 44% when GH secretion during sleep was evaluated, in 25% when pharmacological tests were performed, and in 13% when both methods were applied. Similar results were reported by other authors [Tassoni et al., 1990; Tauber et al., 1997; Aimaretti et al., 2000a] . These results do not only question the previous methods to diagnose idiopathic isolated GH in children, but also the persistence of the disorder during adult life.
In view of these difficulties in correctly classifying patients, it is therefore prudent to start with a simple procedure, such as the exercise test or the measurement of urinary GH, before embarking on formal tests, two of which should always be carried out. (The measurement of spontaneous GH secretion may substitute for one of them.) With this approach, the likelihood of misclassification is reduced.
However, it must be pointed out that a patient with a disorder of the GH axis may well show a GH level above the chosen cut-off level (error of the first order). Depending on certain circumstances, including the GH values arrived at and the stimulatory potency of the test used, such a patient might be deprived of further evaluation, or proper diagnostic classification with regard to the underlying abnormality, and, consequently, deprived also of therapy with GH or IGF. The problem of proper classification is further exemplified when two clinically identical patients are compared, one with a result for the first test that is above the cut-off point, with no further testing, and the other with an outcome for the last of four tests that is above the cut-off point. Even though by the specified rules, both patients would qualify as non-GH-deficient (i.e., each having a test result for one test above the cut-off), it is obvious that we could correctly assume a certain degree of impaired GH secretion in the second patient. Thus, the evaluation of test results requires careful judgement on the part of the investigating physician [Andersson et al., 1995] in order to avoid the improper interpretation of cut-off levels, e.g., by a third party.
The determination of IGF-I (or IGFBP-3) levels rather than GH as the first step toward establishing a disorder of the GH axis implies other advantages and disadvantages. One advantage is that normative data (based on age or any other physiologically relevant parameter) can be obtained relatively easily [see Blum, this volume]. Another obvious advantage is that disorders of the GH axis other than GH secretion can de defined (see table 1 ). On the other hand, one disadvantage is that abnormal IGF (or IGFBP) levels per se require a different differential diagnosis of which GHD is only one possibility. However, it is at present beyond doubt that -provided GH levels are determined by means of appropriate methodology -normal levels of IGF or IGFBP automatically exclude the possibility of GHD. In order to avoid an error of the first order at the initial step of the diagnostic work-up, it is however, necessary to use limits that are not too narrow in order to distinguish between a truly normal level and a doubtful or pathological level. The practice of taking basal IGF or IGFBP measurements on two different occasions is also recommended before excluding GHD or embarking on further steps in the diagnostic work-up.
It is evident that, at the present time, diagnosing a disorder of the GH axis is by no means a trivial task and that a single investigation cannot provide a clear answer to a complicated question. Only by the thoughtful use of the tools available can the diagnosis of impaired GH secretion be made in an individual patient. It should also be kept in mind that a thorough and careful diagnostic work-up is justified in light of the consequences of either long-term treatment or failed therapy.
Methodological Aspects of GH Measurement
Human GH levels in plasma have up to very recently been determined solely by means of the radioimmunoassay (RIA). Commonly, polyclonal antibodies against pituitary-derived GH from rabbits are employed. As with other hormonal compounds, the measurements of GH in blood by means of immunoassays reflect the methodological development over time. Initially, GH levels were measured exclusively by means of the RIA employing radiolabelled pituitary GH. The reference preparations for GH also constituted pituitary human GH such as IRP 66/217, issued by the National Institute for Biological Standards and Control (Holly Hill, UK) or a reference preparation (HS 2243 E) prepared by the National Hormone and Pituitary Program (NHPP) (Bethesda, Md., USA). The biological potency of this pituitary-derived and extensively analyzed reference material, which consists of about 95% monomeric GH, is approximately 2 IU/mg. Most of the currently commercially available assays employ IRP 80/505 (pituitary GH with a potency of 2.6 IU/mg). The new standard preparation (IRP 88/624, employing 22 kD recombinant hGH with a potency of 3.0 IU/mg) will probably be used more widely in the future [Bristow et al., 1995] . It has also been common practice to express GH levels in nanograms per milliliter (ng/ml) or micrograms per liter (g/l). The advantage of carrying out an immunoassay with the pituitary-derived reference preparation is that it contains all the GH components usually found in the circulation [Chawla et al., 1983; Baumann, 1991] . The polyclonal antibody against this material also usually recognizes the various immunogenic epitopes of GH. Thus, GH levels measured in blood have tended to reflect total circulating GH with respect to biological activity.
Recently, a number of assay systems have become available which employ monoclonal antibodies and use biosynthetic recombinant GH for standard and tracer. The assays offer a number of practical advantages such as automatization and speed as well as an increase in sensitivity, and offer a new dimension in physiological studies [Veldhuis, 1996] . This development has created some problems: the specificity of some of the antibodies against some epitopes of the GH molecule and the monomeric nature of the standard can lead to incomplete recognition of the circulating GH components and, consequently, to lower readings [Chatelain et al., 1990; Granada et al., 1990] . Even though both the advantages and the high quality of such assays cannot be disputed, users of these new assays are obliged to establish their own empirical reference levels of normality for the interpretation of the results. Certainly, this strategy should generally be followed by anybody who wants to draw conclusions from laboratory data. However, through experience with the previously available methods, the medical community has gained some confidence in the comparability of GH levels from different sources.
In order to selectively measure the biologically relevant part of circulating GH, radioreceptor assay (RRA) [Gavin et al., 1982] and bioassay methods have also been developed [Tanaka et al., 1980; Dattani et al., 1996; Rowland et al., 2002; Rowlinson et al., 1998 ]. These technically sophisticated and exacting methods are valuable research tools, but not relevant to common clinical problems.
Based on the understanding of the functioning of the GH reception [Leung et al., 1987] a new assay system, termed immunofunctional assay (IFA) has been devised [Strasburger et al., 1996 [Strasburger et al., , 1997 Fisker et al., 1996] . Its design is based on the fact that signaling through the GH receptor occurs only in the event of a GH molecule binding to the extracellular domains of two GH receptor units. This requires binding of the receptor to two different epitopes of the GH molecule. Consequently, the IFA uses two specific monoclonal antibodies to recognize a GH molecule, thus imitating the natural linkage of GH to its receptor. Unfortunately, the extracellular domain of the GH receptor is shed and circulates in blood, keeping the ability to also bind GH [Baumann, 2001] . This GH-binding protein can interfere with the IFA [Ebdrup et al., 1999] . The role of IGFs in the diagnostics of GH secretion disorders has not yet been fully established.
Standardization of GH measurement remains an important issue [Ranke et al., 1999] . Despite the economical pressures, (pediatric) endocrinologists need to attempt to maintain control over the quality of measurements of essential hormones.
Regulation of GH Secretion
The mechanisms of GH release are complex. The interested reader should refer to articles reviewing this rapidly evolving field in more detail [Berthelier et al., 1989; Camanni et al., 1989; Pombo et al., 2001 ]. However, a brief summary of the mechanisms involved will be given here. The major components of GH regulation are GH-releasing hormone (GHRH), which is stimulatory, and GH release-inhibiting hormone (GHRIH), also referred to as somatostatin, which inhibits the pituitary somatotropes (see fig. 1 ). The site of GHRH production is predominantly in the arcuate nucleus, while the production of GHRIH occurs predominantly in the paraventricular nucleus of the hypothalamus. The secretion of both hypothalamic hormones is regulated via a neuronal network. A variety of neurotransmitter substances interact with specific receptors, exerting positive or negative effects at the sites of hypothalamic hormone production. The major receptor sites have binding properties for adrenergic, dopaminergic, serotoninergic and cholinergic transmitter substances. A multitude of substances interact with these (and other) receptors in an agonistic
